Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Year of publication
- 2020 (14) (remove)
Document Type
- Journal article (14) (remove)
Language
- English (14) (remove)
Keywords
- multiple myeloma (6)
- relapse (4)
- refractory (3)
- 18F-FDG PET/CT (2)
- 11C-Methionine PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- AKT-signaling (1)
- B cell (1)
- B cells (1)
- CAR T cell (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- CD38 (1)
- KRAS (1)
- MAPKAPK2 (1)
- MEK/ERK-signaling (1)
- MOR202 (1)
- Pom‐PAD‐Dara (1)
- T cell (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TSLP (1)
- acute lymphoblastic leukaemia (1)
- amplicon sequencing (1)
- blinatumomab (1)
- carfilzomib (1)
- clinical trial (1)
- corticosteroids (1)
- daratumumab (1)
- donor-cell leukemia (1)
- extramedullary disease (1)
- fungal infection (1)
- galactomannan (1)
- genetic susceptibility (1)
- hematologic malignancies (1)
- hematological malignancies (1)
- incidence (1)
- invasive aspergillosis (1)
- life-threatening side-effects (1)
- management (1)
- mantle cell lymphoma (1)
- monocytes (1)
- mortality (1)
- natural killer cell (1)
- novel therapies (1)
- obinutuzumab (1)
- pathophysiology (1)
- pattern (1)
- progression (1)
- radiogenomics (1)
- serum biomarkers (1)
- smoldering myeloma (1)
- stem cell transplantation (1)
- toxicity (1)
- tumor‐specific antigen (1)
- venetoclax (1)
Institute
- Medizinische Klinik und Poliklinik II (14)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Pathologisches Institut (2)
- Institut für Humangenetik (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Virologie und Immunbiologie (1)
- Neurologische Klinik und Poliklinik (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 19-COP-0031 (1)
- 733297 (1)
- 754658 (1)
- 847507 (1)
- 853988 (1)
Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐cell engager) technology is a targeted immuno‐oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor‐specific antigens, allowing off‐the‐shelf immuno‐oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B‐cell non‐Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small‐cell lung cancer). BiTE molecules with an extended half‐life relative to the canonical BiTE molecules are also being developed. Advances in immuno‐oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
(2020)
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.
Delayed natural killer (NK) cell reconstitution after allogeneic stem cell transplantation (alloSCT) is associated with a higher risk of developing invasive aspergillosis. The interaction of NK cells with the human pathogen Aspergillus (A.) fumigatus is mediated by the fungal recognition receptor CD56, which is relocated to the fungal interface after contact. Blocking of CD56 signaling inhibits the fungal mediated chemokine secretion of MIP-1α, MIP-1β, and RANTES and reduces cell activation, indicating a functional role of CD56 in fungal recognition. We collected peripheral blood from recipients of an allograft at defined time points after alloSCT (day 60, 90, 120, 180). NK cells were isolated, directly challenged with live A. fumigatus germ tubes, and cell function was analyzed and compared to healthy age and gender-matched individuals. After alloSCT, NK cells displayed a higher percentage of CD56\(^{bright}\)CD16\(^{dim}\) cells throughout the time of blood collection. However, CD56 binding and relocalization to the fungal contact side were decreased. We were able to correlate this deficiency to the administration of corticosteroid therapy that further negatively influenced the secretion of MIP-1α, MIP-1β, and RANTES. As a consequence, the treatment of healthy NK cells ex vivo with corticosteroids abrogated chemokine secretion measured by multiplex immunoassay. Furthermore, we analyzed NK cells regarding their actin cytoskeleton by Structured Illumination Microscopy (SIM) and flow cytometry and demonstrate an actin dysfunction of NK cells shown by reduced F-actin content after fungal co-cultivation early after alloSCT. This dysfunction remains until 180 days post-alloSCT, concluding that further actin-dependent cellular processes may be negatively influenced after alloSCT. To investigate the molecular pathomechansism, we compared CD56 receptor mobility on the plasma membrane of healthy and alloSCT primary NK cells by single-molecule tracking. The results were very robust and reproducible between tested conditions which point to a different molecular mechanism and emphasize the importance of proper CD56 mobility.